"10.1371_journal.pone.0090768","plos one","2014-03-06T00:00:00Z","Ian Louis Ross; Ragnhildur Bergthorsdottir; Naomi Levitt; Joel Alex Dave; Desmond Schatz; David Marais; Gudmundur Johannsson","Division of Endocrinology, Department of Medicine, University of Cape Town, Cape Town, South Africa; Department of Endocrinology, Institute of Medicine, Sahlgrenska University Hospital, University of Gothenburg, Gothenburg, Sweden; Department of Paediatrics, University of Florida, Gainesville, Florida, United States of America; Division of Chemical Pathology, Clinical Laboratory Sciences, National Health Laboratory Service, University of Cape Town, Cape Town, South Africa","Performed the experiments: ILR RB DM GJ. Analyzed the data: ILR RB NL JD GJ. Contributed reagents/materials/analysis tools: DM GJ. Wrote the paper: ILR RB NL JD DS DM GJ. Conceived the study and designed the study: ILR. Co-designed the study: RB. Co-authored the manuscript: NL. Designed experiments: JD DS. Conceived study and designed experiments: DM GJ.","Prof NS Levitt is a PLOS ONE Editorial Board member. GJ has had equity in DuoCort Pharma. GJ has developed PlenadrenÂ® a modified release formulation for glucocorticoid replacement therapy. The product and related patents are owned by Viropharma. GJ is employed by the University of Gothenburg and acts as a consultant for Viropharma. The global patent is: POSOLOGY AND ADMINISTRATION OF GLUCOCORTICOID BASED COMPOSITIONS WO 2011/144327 Al. Global application: Mimicing glucorticoid diurnal variation and cardiovascular effects EP20111002466. This does not alter the authors' adherence to all PLOS ONE policies on sharing data and materials.","2014","03","Ian Louis Ross","ILR",7,TRUE,1,4,5,7,TRUE,TRUE,FALSE,0,NA,FALSE
